Development and Evaluation of a new technological way of engaging patients and enhancing understanding of drug tolerability in early clinical development: PROACT.
Affiliation
Manchester Cancer Research Centre, University of Manchester, Manchester, UKIssue Date
2016-05-11
Metadata
Show full item recordAbstract
During early clinical testing of a new medication, it is critical to understand and characterise patient tolerability. However, in early clinical studies, it is difficult for patients to contribute directly to the sponsors' understanding of a new compound. Patient reported opinions about clinical tolerability (PROACT) provides a new, simple and innovative way in which patients can collaborate using an application downloaded to a mobile computer or smartphone.Citation
Development and Evaluation of a new technological way of engaging patients and enhancing understanding of drug tolerability in early clinical development: PROACT. 2016: Adv TherJournal
Advances in TherapyDOI
10.1007/s12325-016-0335-4PubMed ID
27167621Type
ArticleLanguage
enISSN
1865-8652ae974a485f413a2113503eed53cd6c53
10.1007/s12325-016-0335-4